Convergent Therapeutics is a clinical-stage pharmaceutical company focused on developing next generation radiopharmaceutical therapies for prostate and other cancers. The company's proprietary technology involves dual-targeted radionuclide therapy that has been licensed to Convergent by Cornell University (USA). If FDA-approved, its flagship therapeutic would be the first antibody approved to direct a radioisotope to prostate cancer.
Dr Kantoff is a board-certified physician in internal medicine and medical oncology; a member of numerous professional societies and editorial boards; author of more than 500 articles and books; and has lectured throughout the world on the topic of cancer treatments. He has been honored with the Harvard Medical School Kantoff-Sang Lectureship Award, and recognized with the first Prostate Cancer Foundation Mentor of Excellence Award.
In this episode, we cover raising money in difficult climates, the important “engine of discovery” that is the biotech industry, and dealing with the unpredictable both as a physician and a company CEO.
You can find out more about Convergent Therapeutics in the following ways:
Website: https://convergentrx.com/
Twitter: https://twitter.com/ConvergentRx
LinkedIn: https://www.linkedin.com/company/convergent-therapeutics/
Find us on:
www.founders-keepers.com
Instagram: @founderskeepers.pod
Twitter: @founders.pod
LinkedIn: https://www.linkedin.com/company/founders-keepers-podcast
Get in touch: hi@founders-keepers.com
#32 Dr Philip Kantoff - Radiopharmaceutical cancer targeting with Convergent Therapeutics